Piflufolastat F-18 (Dcfpyl F-18; Pylarify), the F-18 labeled form of DCFPYL, is a novel and potent PSMA-targeted PET (positron emission tomography) agent approved by FDA in 2021 for diagnosis of prostate cancer. Specifically, it is used to identify prostate-specific membrane antigen-positive lesions in prostate cancer.

纯度：≥98%

CAS：1207181-29-0